Unveiled: Underdog Firm Posts Surprising Gains Amidst Google's Struggles
McKesson's Remarkable Success Story:
Meet McKesson, the key player punching above its weight in the tech world. Unlike digital titans like Google or Amazon, McKesson's profit margins hover around a miserly 1%. But its stock has seen a staggering 4x surge in the last five years, for reasons we're about to uncover. Let's delve into the details of McKesson's extraordinary growth.
Since 2020, McKesson's stock has skyrocketed by an impressive 284%, fueled by strategic initiatives rather than some fancy algorithms. Here's the lowdown:
- P/E Ratio Boost: Its P/E ratio hiked by a whopping 97%, from a humble 11x in 2020 to a hefty 22x today.
- Revenue Roar: Over the same period, revenues grew by an astounding 49%, soaring from $231 billion to $345 billion.
- Share Reduction: McKesson's share count dropped by 28%, thanks to share buybacks worth $13 billion over the past five years.
- Slight Profit Margins Drop: However, McKesson's net income margin took a minor hit, dipping from 1.2% to 1.1% over this period.
In contrast, Google's stock growth—92%—was driven primarily by a whopping 174% increase in earnings per share, from $2.93 in 2020 to $8.04 in 2024. Yet, its P/E ratio saw a 30% decline during the same period, from 30x to 21x.
Now let's dig deeper into the factors propelling McKesson's stellar performance.
Behind the Scenes: McKesson's Success
McKesson's revenue explosion can be largely attributed to three main factors:
- COVID Response: McKesson played a pivotal role in the U.S.'s COVID response, acting as the government's central distributor for vaccines, tests, and medical supplies. This played a significant part in boosting revenue during the pandemic.
- Broadening Horizons: McKesson expanded its pharmaceutical distribution business, cashing in on the escalating demand for specialty pharmaceuticals, particularly critical in oncology and other complex therapeutic areas known for their high-profit margins.
- Mayhem of Medicine: The growth in McKesson's pharmaceutical distribution segment was propelled by several factors, such as higher prescription volumes, especially for specialty products, national retail accounts, and GLP-1 medications.
On top of the revenue growth, McKesson's net income surged by 40%, from $2.7 billion in 2020 to a hefty $3.8 billion today. But its net margin took a negligible hit, slipping by 10 basis points (bps) to 1.1% over the same period.
McKesson's Valentines to Wall Street:
McKesson's P/E ratio has more than doubled since 2020, thanks to its strategic shift towards more profitable segments like specialty pharmaceuticals, oncology services, and tech solutions. Investors have warmly welcomed McKesson's strategic transformation, drastically increasing the company's valuation multiple.
The company's outstanding performance extends beyond its valuation. For instance, while Google plummeted by over 30% in 2022, McKesson enjoyed gains of more than 50%. This remarkable performance is due to McKesson's critical role in healthcare infrastructure, making it an attractive choice for investors seeking stable investments amid economic uncertainties.
Ready to Sail the Safe Shores?
You tired of the rollercoaster ride that comes with individual stocks? Consider diving into the Trefis High-Quality Portfolio, a curated mix of 30 stocks that have consistently outperformed the S&P 500 since its inception, offering smoother sailing with impressive returns exceeding 91%.
Hit the High Seas with Trefis
Market-Beating Portfolios | Rules-Based Wealth
- McKesson has managed to sustain its impressive growth despite having a low profit margin of 1%, showcasing the potential of leveraging diverse business segments like specialty pharmaceuticals, oncology services, and tech solutions for sustainable growth.
- While the stock of digital behemoths like Google has seen varying growth patterns, McKesson has particularly shone during economic uncertainties, demonstrating the value of investing in companies that provide essential services, such as healthcare infrastructure.
- As a result of McKesson's strategic transformation and focus on profitable segments, its stock has seen a remarkable surge of 284% since 2020, making it an attractive choice for investors, especially amid current economic challenges.
